未登录Stable or at least once HER2-low status during neoadjuvant chemotherapy confers survival benefit in patients with breast cancer
Zhao, Yingying; Chen, Xinru; Wang, Yaohui; Zhang, Xueqing; Ye, Yumei; Xu, Shuguang; Zhou, Liheng; Lin, Yanping; Lu, Jingsong; Yin, Wenjin
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏Neo-peripheral adaptive immune score predicts neoadjuvant chemotherapy for locally advanced breast cancer
Wang, Huiling; Sheng, Xiaonan; Yan, Tingting; Xu, Yaqian; Wang, Yaohui; Lin, Yanping; Zhang, Jie; Ye, Yumei; Xu, Shuguang; Zhou, Liheng; Yin, Wenjin; Lu, Jinsong
分享
收藏Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (NeoATP): Primary Analysis of a Phase II Study
Yin, Wenjin; Wang, Yaohui; Wu, Ziping; Ye, Yumei; Zhou, Liheng; Xu, Shuguang; Lin, Yanping; Du, Yueyao; Yan, Tingting; Yang, Fan; Zhang, Jie; Liu, Qiang; Lu, Jinsong
分享
收藏
分享
收藏Efficacy, safety and survival of neoadjuvant chemotherapy with different estrogen deprivation stratified by menstrual status versus chemotherapy alone in locally advanced breast cancer (SHPD002)-A randomized multicentre, open-label, phase 3 Triab
Zhou, Liheng; Xu, Shuguang; Xue, Xiaohong; Zhang, Yinzhou; Gu, Bei; Lin, Baoxing; Bai, Junwen; Zhang, Hongwei; Wu, Kejin; Lin, Yanping; Ye, Yumei; Du, Yueyao; Sheng, Xiaonan; Xu, Yaqian; Zhang, Jie; Yin, Wenjin; Lu, Jinsong
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏